Oxford Immunotec Global PLC Form 3 January 06, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

A Keiley Elizabeth M

(Last)

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Statement

(Month/Day/Year)

01/01/2015

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O OXFORD IMMUNOTEC GLOBAL, Â 94C INNOVATION DRIVE

(Street)

10% Owner Director _X__ Officer Other

(Check all applicable)

Oxford Immunotec Global PLC [OXFD]

(give title below) (specify below) VP & General Counsel

6. Individual or Joint/Group

Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

ABINGDON. OXFORDSHIRE, X0Â OX14 4RZ

(City) (State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of Price of Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Derivative Security:

Edgar Filing: Oxford Immunotec Global PLC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Share Option (Right to Buy) (1)	(2)	09/30/2022	Ordinary Shares	11,185	\$ 0.81	D	Â
Share Option (Right to Buy) (3)	(4)	01/01/2024	Ordinary Shares	6,030	\$ 22.99	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
Keiley Elizabeth M C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE ABINGDON, OXFORDSHIRE, X0 OX14 4RZ	Â	Â	VP & General Counsel	Â	

Signatures

/s/ Elizabeth M.
Keiley

**Signature of Reporting Person

O1/06/2014

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option granted under Issuer's Amended and Restated 2008 Stock Incentive Plan.
- (2) Currently exercisable as to 6,291 shares, and will become exercisable as to the remainder ratably on the first of each month from February 1, 2015 through October 1, 2016.
- (3) Option granted under Issuer's 2013 Share Incentive Plan.
- (4) Currently exercisable as to 1,507 shares, and will become exercisable as to the remainder ratably on the first of each month from February 1, 2015 through January 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2